Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial Post author:admin Post published:March 12, 2025 Post category:uncategorized Post comments:0 Comments NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. You Might Also Like Low-Carb Peanut Butter Granola February 9, 2024 Breakthrough model simulates human bone marrow function in the lab January 31, 2025 There’s a new covid-19 variant and cases are ticking up. What do you need to know? January 8, 2024 Leave a Reply Cancel replyYou must be logged in to post a comment.